Enhanced translation of Epstein-Barr virus nuclear protein, EBNA1, as a target for T cell-based immunotherapy.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/496684

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Epstein-Barr virus, (EBV) is a human herpesvirus associated with a range of human cancers. EBNA1, an important EBV antigen, was thought to be immunologically silent however, recent studies from our laboratory show that EBNA1 is recognized by our body's defence system and these observations raise the possibility that EBNA1 may be an exploitable, immuno-therapy target for treating EBV-associated cancers.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2011

Funding Scheme: NHMRC Project Grants

Funding Amount: $276,598.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Antigen processing | Cancer biology | Cytotoxic T lymphocytes | Immunotherapy | Infectious diseases | Viral immunity | Viral infection | tumour immunotherapy

Related Links